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1653 doses of vaccines were injected. The three- dose schedule
was given to 414 (66%) girls and 2-dose schedule to 198 (31.6%)
girls. Vaccine safety assessment was carried out. Adverse effects
were observed in 9.6% of cases and were mainly characterized by
dizziness and pain at the injection site. Vaccination was well
tolerated.
When calculating socio-economic feasibility of the proposed
technology , not only the economic damage caused by the high
mortality of women from cervical cancer, but also the cost for
treatment of precancerous cervical lesions were taken into
account, as out of 25 women with undetected CINII-III, 10 will
develop cervical cancer. There have been calculated the esti-
mated damage from cervical cancer in the Tomsk region, which
takes into account not only the cost of diagnosis and treatment
of cervical pre-cancer, but also losses associated with temporary
permanent disabilities (social benefits, including disability pen-
sion before the age of 55 years). Calculations show that the total
economic damage caused by the management of patients with
cervical cancer, can be from 20 to 40 mln. rubles per year.
Thus, primary prevention of cervical cancer, taking into
account the prevalence of HPV infection and economic impact
of cervical cancer can be considered as an effective technology
for public health that will allow preservation of not only
reproductive but also employment potential of women of Tomsk
region.
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Background: Myelofibrosis with myeloid metaplasia is chronic
mieloproliferative disease with ineffective erythropoiesis,
dysplastic-megakaryocyte hyperplasia, and an increase in the
ratio of immature granulocytes to total granulocytes. The
incidence rate is 3.7–5.7 per 100,000 and the median survival is
estimated to be between three and six years. The pathogenesis
of myelofibrosis might be explained, in part, by a somatic point
mutation on exon 14 (V617F) of the JAK2 kinase gene that is
located on chromosome 9p24. However, mechanisms of regula-
tion of microenvironment in bone marrow fibrosis are not clear.
Considered that main producents of pro-fibrotic factors are the
megakaryocytes and the macrophages. In this study we investi-
gated influence of platelet factors on the cellular characteristics
of the macrophages with oncogenic mutation JAK2 V617F.
Materials and Methods: THP-1 cell line wasmodified by lentivi-
ral modification. Two cell lines established: one with expression
of JAK2 with oncogenic mutation JAK2 V617F, another wild type
JAK2. Cells were cultured in RPMI-1640 containing 0.1% gentam-
icin, 1% l-glutamine and 10% fetal bovine serum (FBS) or 5%,
10% and 15% platelet lysate (PL). Cell lines were differentiated into
the macrophages using 50 ng/ml phorbolmyristate acetate (PMA).
Level of expression transforming growth factor b (TGFb), galectin-
3, matrix metalloproteinases (MMP) 2, 9, 12, 13 and tissue inhibi-
tors of matrix metalloproteinase (TIMP) accessed by specific RT-
qPCR.
Results: We observed increased expression level of galectin-3,
MMP-2, MMP-13 and TIMP-3 in JAK2 V617F expressing macro-
phages cultured with 10% FBS compare to ones with WT JAK2.
Also macrophages containing mutation JAK2 V617F has increased
level of expression of MMP-2, TIMP-3 and TIMP-4 when cultured
with 10% platelet lysate. Also, cell line containing mutation
JAK2 V617F has increased levels of expression of MMP-12 for cells
cultured with 15% PL. We did not observe any significant
difference in expression of TGFb, MMP-9, TIMP-1 and -2.
Conclusion: Increased levels of expression of galectin-3, MMP-
12 and -13 suggest that platelet factors induce macrophages with
JAK2 V617F mutation to release of profibrotic factors. On the other
hand, increase of antifibrotic MMP-2 and TIMP-3 revealing
complex nature of melofibrosis development and need to be
analyzed further.
This study confirms the idea of interaction between macro-
phages and platelets in pathogenesis of primary myelofibrosis.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.097
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High dose IL-2 (HD IL-2) has been extensively used as an
immunotherapy against metastatic melanoma However, why
HD IL-2 is effective only in a subset of patients and whether pre-
dictive biomarkers, before or early during the course of therapy,
can be used to improve response rates remain unresolved. In
addition, it has been found that IL-2 therapy potently expands
CD4+CD25+Foxp3+ T-regulatory cells (Tregs) but how Treg cell
levels, phenotype, and function change and whether specific sub-
sets of Tregs are activated and expanded during HD IL-2 therapy is
remain unclear. In this study, we performed comprehensive
multi-parameter FACS analysis of patient blood before and two
days after the last bolus of IL-2 infusion during cycle 1 of HD
IL-2 therapy. Two lymphocyte subsets were found to expand the
most during the first cycle of IL-2 therapy: CD4+CD25+Foxp3+
Tregs expressing an activation marker, inducible costimulator
(ICOS), and CD3-CD56hiCD16loPerforin+ NK cells. ICOS+ Tregs
expressed significantly higher levels of CD25, Foxp3 and had a
more activated phenotype than ICOS Tregs as indicated by lower
levels of CD45RA and CD127 expression. Further phenotypic char-
acterization revealed a more suppressive phenotype on ICOS+
Treg with higher expression levels of CD39, CD73, and TGF-b/
LAP than ICOS Treg. ICOS+ Tregs were also the predominant
Treg cells that secreted IL-10 and have potent T-cell suppressor
function. Majority of ICOS+ Tregs from HD IL-2-treated patients
were Ki67+ and exhibited an enhanced proliferative response to
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IL-2 ex vivo relative to ICOS Tregs. Functional analysis revealed
that ICOS+ Tregs secreted little IFN- and IL-2 in comparison to
CD4+Foxp3 – cells. Furthermore, analysis on 38 IL-2-treated
patients at MD Anderson, we found that non-responders had a
significantly higher degree of ICOS+ Treg expansion than respon-
ders during the first cycle of IL-2 therapy, while no significant
changes in the ICOS or bulk Treg population. In conclusion,
our data suggests that tracking changes in ICOS+ Tregs early
during the course of HD IL-2 therapy may be a new predictive
biomarker of clinical outcome.
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Renal cell carcinoma (RCC) is the most widespread kidney
tumor, which originates mostly from distal kidney tubules. RCC
is the major mortality cause in excretory system cancer in adults,
and constitutes about 80% of various kidney cancers. The 5-year
survival rate is 60–70%, but lowers significantly in case of metas-
tasis formation. The tumor is relatively resistant to chemother-
apy and radiation therapy, but responds to immunotherapy.
Target drugs (e.g. sunitinib, bevacizumab, a-interferon, sorafenib)
are more preferable in RCC therapy. In most cases RCC is caused
by obesity, smoking, arterial hypertension and hereditary factors.
4 patients of Voronezh Regional Clinical Oncology Center, aged
from 50 to 75 years old were enrolled in this study. All were diag-
nosed with renal cell carcinoma confirmed by immunohisto-
chemical analysis.
Gene expression profiling was performed using Affymetrix
GeneAtlas system with Affymetrix Hunam Gene 1.1 ST DNA-
microarrays. Data moralization, statistical analysis and differen-
tially expressed genes (DEG) list creation were performed using
Partek Genomics Suite v. 6.6. DNA samples were sequenced on
Ion Proton sequencer with Comprehensive Cancer Panel primer
pool. Subsequent pathway analysis and biological interpretation
were conducted using Ingenuity Pathway Analysis system and
Ion Reporter Suite.
3528 genes were differentially expressed with expression
change more than 2 times, and 351 genes changed their expres-
sion more than 5 times (p-value <0.05).
Only mutations causing either amino-acid substitution in cor-
responding protein, open reading frame shift, or truncated tran-
script formation were taken into account. Targeted DNA
sequencing revealed 99 common mutations in normal tissues of
all test subjects. 14 mutations were localized in SDHB, TRIM33,
PDE4DIP, PBX1, ABL2, MTR, VHL, ROS1, PRKDC, CSMD3, MLLT10,
TRIP11, PER1, genes and were tumor-specific in all patients.
33 mutations were localized in promoter regions of EGFR, PDGFRA
and HNF1A genes.
The most representative metabolic and signaling pathways
according to Ingenuity knowledge base were ‘‘FXR/RXR
Activation”, ‘‘Atherosclerosis Signaling”, ‘‘LXR/RXR Activation”,
‘‘Production of NO and ROS in Macrophages”, ‘‘Cell migration
and adhesion”. Five most downregulated genes among all
patients were CALB1 (187), HPD (133), KNG1 (126), SLC36A2
(126) and PAH (122). Five most upregulated genes were
TNFAIP6 (+34), ANGPT2 (+23), SERPINE1 (+22), CP (+20), HILPDA
(+20).
Genes with mutations and differentially expressed genes were
simultaneously included in pathways analysis in order to gener-
ate gene networks with possible upstream regulators (mutated
genes) included. This allowed observing a number of gene inter-
actions not present in existing reports.
This method of genomic and transcriptomic data integration
allowed us to determine the sources of mRNA level variation. A
number of mutations and specific DEGs discovered in this study
are not registered in existing databases of annotated mutations,
which allows us to propose population heterogeneity of RCC
causes. These DNA mutations and mRNA level changes could
be used as predictive biomarkers of renal cell carcinoma.
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Background: Cancer cells attractive and activate many non-
tumoral cells, including bone marrow-derived cells, as a result
stimulate migration of this cells. Many studies demonstrate that
tumor causes active redistribution of bone marrow cells during
specific stages of cancer progression and metastasis. However,
to date how the bone marrow derived cells at primary sites is
hijacked to support tumor growth and how tumor progression
influence of bone marrow cells distribution is not understood.
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